This story is from the CurrentWire archive. Coverage details reflect the last time it was updated.
858 Therapeutics Announces FDA Fast Track Designation for PARG Inhibitor ETX-19477 for the Treatment of Patients with BRCA-Mutated, HR+/HER2- Unresectable or Metastatic Breast Cancer
— Fast Track designation granted by U.S. FDA for evaluation of ETX-19477 in patients with BRCA-mutated HR+/HER2- unresectable or metastatic breast cancer — — Enables access to expedited regulatory review processes, including potential eligibility for accelerated approval and priority review — — Ongoing Phase 2 monotherapy cohorts in BRCA-mutated ovarian and breast cancer — SAN […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Source mix
1 independent editorial domain
Coverage
1 publication is covering this story.
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.